Epredia, a cancer diagnostics specilaist, is to distribute AI-powered image‑recognition software, by Mindpeak, to digital pathology customers across the European Union.
The two companies framed the deal as a response to growing diagnostic complexity and pressure on pathology laboratories to accelerate workflows and lower costs as cancer care demand rises.
Mindpeak’s software provides instant, pixel‑level analysis of digital tissue images to support objective, reproducible assessment in breast cancer, lung cancer, gastrointestinal pathology, biomarker quantification and research studies. The tools operate without requiring cloud connectivity and the company’s portfolio includes both CE Marked and research‑use‑only modules, the companies said.
Epredia will offer Mindpeak modules for clinical diagnostics, translational research and pharmaceutical development, and intends to investigate integration into its E1000 Dx Digital Pathology Solution - which is described as a high‑speed, automated whole‑slide imaging system that can handle up to 1,500 high‑resolution digital images daily - to enable streamlined data exchange.
“Epredia is committed to providing the right tool at the right time to help pathology labs deliver accurate, efficient diagnoses of cancer, so patients can get the care they need,” said Steven Lynum, President of Epredia.
The recap
Epredia will distribute Mindpeak AI software to EU customers
E1000 Dx can review up to 1,500 high‑resolution images daily
Epredia will explore integrating Mindpeak into E1000 Dx workflow